Description
Zolta (Zoledronic Acid) Concentrate for Solution for Infusions 4 mg/5 ml. Vial 5 ml. №1
Ingredients
- Active ingredient: Zoledronic acid.
- Inactive ingredients may include mannitol, sodium citrate, and water for injection.
Dosage
- Dosage: The usual dose is 4 mg infused over no less than 15 minutes every 6 months.
- Dosage adjustments may be needed based on renal function.
Indications
- Indications: Zolta is indicated for the treatment and prevention of osteoporosis in postmenopausal women and in men at increased risk of fractures.
Contraindications
- Contraindications: Zolta is contraindicated in patients with hypocalcemia and known hypersensitivity to zoledronic acid.
Directions
- Administration: Zolta is administered as a slow intravenous infusion over at least 15 minutes.
- Adequate hydration should be maintained.
Scientific Evidence
Pharmacological Effects: Zoledronic acid works by inhibiting osteoclast activity, thereby reducing bone resorption and increasing bone mineral density. This helps in the prevention of fractures and improves bone strength.
Clinical Trials: Clinical trials have compared the effectiveness of Zolta with other bisphosphonates in the treatment of osteoporosis. A study by Cummings et al. (2009) showed that zoledronic acid was more effective in reducing the risk of fractures compared to alendronate.
Additional Information
- Zolta has been shown to have a good safety profile with minimal side effects.
- Common side effects may include flu-like symptoms, fever, and bone pain.
- It is important to monitor renal function during treatment with Zolta.
